News

Read the latest updates about BioMarin and learn more about our science, our people and the communities we support.

- Press Releases
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease

October 29, 2026
- Community
- People and Culture
Advocating with Purpose: Stacie Cavallaro on Building Bridges Between Industry and Community

October 30, 2026
- Community
Edoardo Makes Space for Ambitious Goals, Anchored in Family and Passion

October 25, 2026
- Community
RARE Scholars Charting New Paths in Medicine, Advocacy, Leadership and Business

October 21, 2026

Stories

All Stories

Stacie Cavallaro

Advocating with Purpose: Stacie Cavallaro on Building Bridges Between Industry and Community

October 30, 2026

Making Space Featured Image

Community

Edoardo Makes Space for Ambitious Goals, Anchored in Family and Passion

October 25, 2026

RARE Scholars

Community

RARE Scholars Charting New Paths in Medicine, Advocacy, Leadership and Business

October 21, 2026

Arpit Dave

Arpit Davé on Seizing the Opportunity to Accelerate Science and Deliver Greater Impact for Patients

October 19, 2026

Yaniris Silva

Yaniris Silva Reflects on the Power of Life-Changing Opportunities

September 29, 2026

jacob burke

Community

Making Space for Jacob’s Big Dreams, Rooted in Family Support

August 27, 2026

Press Releases

All Press Releases

BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease

October 29, 2026

BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET

October 26, 2026

BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting

October 9, 2026

BioMarin Appoints Cara Bauer as Chief People Officer

October 5, 2026

BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress

October 2, 2026

Company Statements

All Company Statements